{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:06Z","timestamp":1784613906150,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Membranous nephropathy (MN) constitutes an autoimmune glomerular disorder and represents the most frequent etiology of primary nephrotic syndrome in adults. Although obinutuzumab exhibits favorable efficacy in managing refractory MN, outcomes diverge across individual investigations. Consequently, the present meta-analysis is undertaken to systematically evaluate the clinical efficacy and safety of obinutuzumab in individuals with refractory MN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted across the Cochrane Library, Embase, Web of Science, and PubMed to determine relevant clinical investigations published up to November 12, 2025. Treatment effects were quantified employing the pooled proportion rate with 95% confidence interval (CI), mean difference (MD, 95% CI), and standardized mean difference (SMD, 95% CI). Heterogeneity was examined via the I\u00b2 statistic. Subgroup analyses were implemented based on the geographic distribution of the study population and duration of follow-up. All extracted data were subjected to statistical analysis using R (v4.5.2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The present meta-analysis ultimately incorporated 12 articles (222 individuals) after applying the eligibility criteria. Concerning remission rates, the overall clinical remission rate reached 86% (95% CI: 80% to 90%), the complete clinical remission rate stood at 31% (25% to 37%), the partial clinical remission rate was 55% (49% to 63%), and the immunologic remission rate achieved 88% (81% to 92%). Obinutuzumab reduced proteinuria (SMD = \u22121.2, 95%CI \u22121.37 to \u22121.03) and raised serum albumin (MD\u00a0=\u00a012.5, 95%CI 9.91\u201315.08), while eGFR showed no significant change (MD\u00a0=\u00a03.23, 95%CI \u22123.76\u201310.21). The pooled adverse event rate was 29% (95%CI 15%\u201348%), with two fatal pneumonia-related events: severe COVID-19 pneumonia and pneumonia-induced respiratory failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obinutuzumab demonstrates marked efficacy in treating refractory MN, with an overall clinical remission rate of 86% and a low incidence of severe adverse events. This profile signifies a potential therapeutic role for this condition. However, all raw data included in this meta-analysis were derived from uncontrolled retrospective single-arm trials and case series. Given factors such as selection bias, the remission rate may be overestimated. Large-scale, multicenter randomized controlled trials are necessary for verification in future investigations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251231344.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1880420","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:25Z","timestamp":1784612125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Pengli","family":"Cong","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-662-52972-0_20","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv435","article-title":"Long-term outcomes of persistent disease and relapse in primary membranous nephropathy","volume":"31","author":"Kanigicherla","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.12659\/msm.930097","article-title":"A review of the current practice of diagnosis and treatment of idiopathic membranous nephropathy in China","volume":"27","author":"Wu","year":"2021","journal-title":"Med Sci Monit"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa014","article-title":"The evolution of the therapeutic approach to membranous nephropathy","volume":"36","author":"Ponticelli","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: Core curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0b013e32835026ed","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.16781\/j.CN31-2187\/R.20240763","article-title":"Obinutuzumab in treating refractory primary membranous nephropathy: a single-center study","volume":"46","author":"Dong","year":"2025","journal-title":"Acad J Naval Med Univ"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04407-3","article-title":"Observation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy","volume":"57","author":"Li","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.05.004","article-title":"Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy","volume":"9","author":"Su","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-025-02224-6","article-title":"Obinutuzumab in rituximab-resistant and recurrent membranous nephropathy: a case-series","volume":"38","author":"Sridharan","year":"2025","journal-title":"J Nephrol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf026","article-title":"Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy","volume":"18","author":"Su","year":"2025","journal-title":"Clin Kidney J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000545995","article-title":"Additive obinutuzumab achieves high remission rates in rituximab-refractory membranous nephropathy","volume":"57","author":"Li","year":"2026","journal-title":"Am J Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1650054","article-title":"Efficacy and safety of obinutuzumab in primary membranous nephropathy: a real-world retrospective study","volume":"16","author":"Cheng","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf039","article-title":"The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.25259\/ijn_498_23","article-title":"Obinutuzumab in difficult to treat phospholipase A2 receptor positive membranous nephropathy: our experience at a tertiary care center in North India","volume":"35","author":"Jha","year":"2025","journal-title":"Indian J Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin","year":"2024","journal-title":"Kidney Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/0886022x.2024.2416605","article-title":"Effectiveness and safety of B cell-targeting biologics in the treatment of lupus nephritis: a systematic review and network meta-analysis","volume":"46","author":"Zhao","year":"2024","journal-title":"Ren Fail"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2602678","article-title":"Obinutuzumab or tacrolimus in primary membranous nephropathy","author":"Fervenza","year":"2026","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2026.2642796","article-title":"Obinutuzumab for membranous nephropathy: a systematic review using pooled case-level extraction analysis","volume":"81","author":"Atay","year":"2026","journal-title":"Acta Clin Belg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:35:27Z","timestamp":1784612127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1880420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1880420"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1880420","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1880420"}}